You have read all your free articles, to continue reading subscribe to read the rest of this content.
Nordic Nanovector has entered into a collaboration with LegoChem Biosciences, a South Korea-based biopharmaceutical company, to develop novel CD37-targeting antibody-drug conjugates (ADCs) for the treatment of leukaemias. Leukemias are orphan diseases with a significant unmet medical need, represAlready a subscriber Login You have read all your free articles, to continue…
AstraZeneca’s Forxiga has been approved in China to reduce the risk of cardiovascular (CV) death and hospitalization for heart failure (hHF) in adults with heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF). The approval by China’s National Medical Products AdministrationAlready a subscriber Login You have read all your…
The companies have decided to increase their collaboration and, as part of this greater collaboration, Vitrolife has invested in Biolamina together with the company’s present owners. Vitrolife has collaborated with the Stockholm-based Biolamina within the stem-cell field since 2012. During spriAlready a subscriber Login You have read all your free…
Nordic Nanovector has raised MNOK 500 in gross proceeds through a private placement of 4,374,244 new shares. Nordic Nanovector intends to use the net proceeds to fund a Phase 2 combination study of Betalutin® and Rituximab CD20, fund a Phase 1 study and GMP manufacturing for 177Lu-conjugated cAlready a subscriber…
